Hints and tips:
Related Special Reports
...Marc Lipsitch, the director of the government’s Center for Forecasting and Outbreak Analytics and the director of the Center for Communicable Disease Dynamics at Harvard, said: “This is clearly gain of function...
...“The biggest barrier is insurance companies,” said Lawrence Honig, a neurologist at New York’s Columbia University Irving Medical Center....
...Ziyad Al-Aly, R&D chief at Veterans Affairs St Louis Health Care System and clinical epidemiologist at Washington University in St Louis, discovered that patients in the VA’s extensive database who had recovered...
...The Centers for Medicare & Medicaid Services said last month that Medicare Part D drug benefit plans will cover weight loss medicines when they are approved to treat a separate medical problem, such as heart...
...Crab, which causes life-threatening illnesses in hospital patients, is classed as a priority concern by the WHO and an urgent threat by the US Centers for Disease Control and Prevention....
...She was involved for decades with the National Institutes of Health (NIH) in Washington, DC, also working with the Breast Cancer Taskforce at the National Cancer Institute of the NIH, the Harvard School...
...Including clinical trials, it often takes up to a decade to discover and develop a new drug, costing on average about $2.7bn, according to research by the Tufts Center for the Study of Drug Development....
...“There is so little surveillance for fungal infections and resistance around the world that we don’t really know what’s out there,” said Tom Chiller, head of fungal diseases at the US Centers for Disease...
...Roche is conducting phase 1 clinical trials in humans on the candidate drug, which targets a bacterium known as carbapenem-resistant Acinetobacter baumannii, or CRAB....
...Antifungal therapy managed to clear the infection, but the patient still died because of other clinical factors....
...First, the marble is very white, clinical almost. Secondly, although the dome is allowed to glow, every rib and join elsewhere is backlit with bright white LEDs....
...The writer is clinical professor for business and society, and founding director of NYU Stern Center for Sustainable Business Amid a mounting backlash against ESG, critics have argued that investors should...
...“Today’s approval addresses an unmet medical need,” said John Sharretts, director of the diabetes and obesity division in the FDA’s Center for Drug Evaluation and Research in a statement....
...Colleagues at NIH’s Clinical Center were unable to secure matched donor samples from Europe to offer stem-cell transplantation treatment to some cancer patients, despite donor consent....
...Last year the first man to receive a pig’s heart transplant died two months after the operation at the University of Maryland Medical Center....
...Last month, the FDA’s panel of experts unanimously voted that Leqembi does show “clinical benefit”....
...A pre-clinical study in rats with alcohol use disorder showed that it decreased their desire for alcohol. Scientists are now researching the drug as a possible treatment for alcohol use disorders....
...In 2017 the drug failed a clinical trial, triggering a collapse in Axovant’s shares that cost many investors millions of dollars....
...There were almost 112,000 openings for pharmacy technicians, about 30 per cent more than in 2019, according to the Pharmacy Workforce Center, which compiles pharmacy employment data....
...But the primary endpoint in the clinical trial was not met.”...
...Worse vascular health is strongly related to development of clinical Alzheimer’s dementia, she says, pointing to years of research....
...That decision limited reimbursement to patients enrolled in a clinical trial of the drug and caused Biogen to scrap its rollout of Aduhelm....
...John Fetterman, the 53-year-old Democratic senator from Pennsylvania, was admitted to Walter Reed Army Medical Center last month and remains hospitalised for clinical depression....
...In the wake of the controversy over the FDA approval of Biogen’s aducanumab, the US Centers for Medicare and Medicaid Services said only patients taking part in a clinical trial would benefit from reimbursement...
...However, as GSK had privately predicted, the medicine was a flop and in 2017 it failed clinical trials, causing Axovant’s shares to collapse....
International Edition